SUBSCRIBE
SUBSCRIBE

Phase 3

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Regulus Therapeutics, Inc. Gets Seat At Hepatitis C Table With Impressive Phase 1 Results
October 22, 2014
 · 
1 min read
Analysts Not Sold On Medivation’s Xtandi as Breast Cancer Drug
Drug Development
Celgene’s New Crohn’s Disease Drug Impressing Analysts
October 21, 2014
 · 
1 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Novartis AG’s Leukemia Drug CTL01 Clears Cancer In 90 Percent Of Patients
October 15, 2014
 · 
2 min read
Mylan Inc., Theravance, Inc. Partner Up for $265 Million COPD Pact
Drug Development
Novartis AG’s Secukinumab Has Consistent Activity In Psoriasis
October 13, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
SSF-Based Sunesis Pharmaceuticals, Inc.'s Shares Crater After Failed Phase 3 Cancer Drug Study
October 6, 2014
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Novartis AG To Roll Out 15 Abstracts At EADV
October 1, 2014
 · 
1 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Novartis AG Reports Two Positive Phase 3 Trials For Arthritis Drug
September 25, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Gilead Sciences, Inc.'s Single Tablet HIV Regimen Meets Goals In Two Phase 3 Studies
September 24, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Gilead Sciences, Inc.'s Experimental Drug Simtuzumab Fails Mid-Stage Study
September 17, 2014
 · 
2 min read
Analysts Not Sold On Medivation’s Xtandi as Breast Cancer Drug
Drug Development
Analyst: Safety Worries Dog Merck & Co.’s Osteoporosis Drug
September 16, 2014
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer
February 6, 2026
 · 
4 min read
Press Releases
Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo
February 5, 2026
 · 
8 min read
Press Releases
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
February 5, 2026
 · 
8 min read
Press Releases
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 5, 2026
 · 
25 min read
Press Releases
Aicuris Presents Positive Phase 3 Data for Pritelivir in Immunocompromised Patients with Refractory Herpes Simplex Virus at TANDEM
February 5, 2026
 · 
6 min read
Press Releases
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
February 4, 2026
 · 
10 min read
Press Releases
RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy
February 4, 2026
 · 
4 min read
Press Releases
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
February 3, 2026
 · 
9 min read
Press Releases
Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients
February 3, 2026
 · 
12 min read
Press Releases
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
February 3, 2026
 · 
6 min read
Press Releases
Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites
February 2, 2026
 · 
2 min read
Press Releases
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
February 2, 2026
 · 
4 min read
Press Releases
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
February 2, 2026
 · 
8 min read
Press Releases
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
February 2, 2026
 · 
14 min read
Press Releases
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
February 2, 2026
 · 
11 min read
Press Releases
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
February 1, 2026
 · 
12 min read
Press Releases
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
February 1, 2026
 · 
12 min read
Press Releases
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
January 30, 2026
 · 
9 min read
Press Releases
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
January 30, 2026
 · 
6 min read
Press Releases
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
January 29, 2026
 · 
7 min read
Load More